Carcinoid clinical trials at UCSF

1 research study open to eligible people

Carcinoid is a rare, slow-growing cancer that can develop in different parts of the body. UCSF is exploring new treatment options for patients with advanced carcinoid tumors. One clinical trial is comparing a new drug to standard treatments for those whose cancer has worsened after prior therapy.

Showing trials for

  • RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

    open to eligible people ages 18 years and up

    This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2 in subjects with inoperable, advanced, well-differentiated, somatostatin receptor expressing (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following treatment with Lutetium 177-labelled somatostatin analogue (177Lu-SSA) therapy, such as 177Lu-DOTATATE or 177Lu-DOTATOC (177Lu-DOTATATE/TOC), or 177Lu-high affinity [HA]-DOTATATE.

    San Francisco, California and other locations

Last updated: